Related Experiment Video

Updated: May 1, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.6K

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

Luana Calabrò1, Michele Maio1

  • 1Medical Oncology and Immunotherapy; University Hospital of Siena; Istituto Toscano Tumori; Siena, Italy.

Oncoimmunology
|April 16, 2014
PubMed

Insights

Tremelimumab, a monoclonal antibody, blocks cytotoxic T lymphocyte-associated protein 4 (CTLA4) to treat refractory malignant mesothelioma. This approach offers a potential new therapy for this deadly cancer with limited options.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors are revolutionizing cancer therapy.
  • Malignant mesothelioma is a deadly cancer with few effective treatments.
  • Cytotoxic T lymphocyte-associated protein 4 (CTLA4) is a key immune checkpoint regulator.

Purpose of the Study:

  • To evaluate the effects of tremelimumab, an anti-CTLA4 monoclonal antibody, in patients with refractory malignant mesothelioma.
  • To explore a novel therapeutic strategy for a fatal malignancy with unmet medical needs.

Main Methods:

  • Administration of the monoclonal antibody tremelimumab.
  • Focus on patients with refractory malignant mesothelioma.
  • Clinical assessment of treatment effects.

Main Results:

  • Tremelimumab demonstrated effects in patients with refractory malignant mesothelioma.
  • Blocking CTLA4 with tremelimumab showed potential in this patient population.

Conclusions:

  • Monoclonal antibody therapy targeting CTLA4, such as tremelimumab, represents a promising avenue for malignant mesothelioma.
  • Further research is warranted to establish the efficacy and safety of tremelimumab in this indication.
Keywords:
anti-CTLA4 antibodyimmunomodulating antibodymesotheliomatherapytremelimumab

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

8.8K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K